OTREXUP PFS (methotrexate) by Teva is folic acid metabolism inhibitors [moa]. First approved in 2013.
Drug data last refreshed 13h ago · AI intelligence enriched 3mo ago
OTREXUP PFS is a subcutaneous solution formulation of methotrexate, a folic acid metabolism inhibitor used to treat autoimmune and malignant conditions. It works by inhibiting dihydrofolate reductase, disrupting nucleotide synthesis and cellular proliferation. The pre-filled syringe (PFS) format offers improved convenience and dosing accuracy compared to traditional formulations.
Product is in peak commercial phase with mature market penetration; sales and marketing teams are likely focused on maintaining market share and managing pricing pressures.
Folic Acid Metabolism Inhibitors
Folate Analog Metabolic Inhibitor
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment
A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together
A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)
A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled Gout
A Multicenter, Prospective Clinical Trial With a Concurrent Control Evaluating Methotrexate Combined With Rituximab,Sintilimab and Pirtobrutinib vs. Investigator-Selected Standard of Care in Treatment-Naive PCNSL
Worked on OTREXUP PFS at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moTeva is hiring 1 role related to this product
LOE in ~5 years — strategic planning for patent cliff underway
OTREXUP PFS positions you in a mature, stable commercial franchise with limited new indication development but strong market presence. Working on this product develops expertise in sustained-yield brand management, payer negotiations, and pre-LOE strategic planning—valuable skills for managing franchise stabilization and lifecycle extension.